Neurocrine Biosciences (NBIX) said Friday the phase 4 study of its Ingrezza treatment for patients with tardive dyskinesia showed improvements in functional and health-related quality of life measures.
Patients with the movement disorder who received the treatment for eight weeks experienced significant improvements in measures such as mobility, self-case, usual activities, and pain/discomfort, the company said.
In a separate analysis, patients who received the treatment also experienced improvements in Sheehan Disability Scale items, including work/school, social life, and family/home life, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.